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We have studied 161 patients with diarrheal disease to determine the frequency
with which Clostridium difficile occurs in such patients. C. difficile or its toxin or
both were detected in stools from 19 patients (11.9%), 17 of whom had previously
received antimicrobial agents. Enteric pathogens other than C. difficile were
recovered less frequently, with Salmonella sp., Giardia lamblia, and Campylo-
bacter fetus being recovered from 4.1, 2.5, and 1.3%, respectively, of the patients
studied. These data suggest that C. difficile may be frequently encountered in
specimens obtained from patients with diarrhea who receive antibiotics and may
play a role in diarrheal disease in such patients.
Clostridium difficile has been implicated as
an important etiological agent in antimicrobial-
associated diarrheal disease and pseudomem-
branous colitis (1, 3, 11). The pathogenicity of
this organism is due to its ability to produce an
extracellular protein that has cytotoxic effects
on cells in tissue culture (6, 7) and can produce
disease in experimental animals similar to that
seen in humans (2, 10). Although the ability of
C. difficile to produce pseudomembranous coli-
tis has been well established (1, 3, 11), the fre-
quency of this organism in a general population
with diarrheal disease has not been well estab-
lished. In addition, the relative frequency of C.
difficile in comparison to other enteric patho-
gens, such as Salmonella sp., Shigella sp., Yer-
sinia sp., Campylobacter fetus, and intestinal
parasites, has not been reported in the United
States. In this paper, we present data that relate
the frequency of isolation of C. difficile to that
of other established enteric pathogens from pa-
tients with diarrheal disease.
MATERUILS AND METHODS
Patient population. The patients examined in this
study were either inpatients or outpatients seen be-
tween March 1979 and April 1980 at the North Caro-
lina Memorial Hospital, a tertiary care facility. All
patients studied had watery diarrhea, which prompted
a request for either bacterial stool culture or stool
examination for ova and parasites. Watery diarrhea
was defined as stools which took the form of the
specimen container and could be easily pipetted with
a pasteur pipette. Multiple specimens were often ex-
amined, with as many as seven specimens examined
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per patient. Cultures for C. fetus, Clostridium difficile,
Salmonella sp., Shigella sp., and Yersinia sp. were
performed within 2 h of collection. Specimens for ova
and parasites were also routinely examined for para-
sites within 2 h of collection. Those specimens sub-
mitted for parasitological examination that could not
be examined within 2 h were mixed with 10% For-
malin-0.85% saline solution until examination. Stools
that were to be assayed for C. difficile toxin were held
at -70°C until assay. All of the patients' charts were
reviewed for diarrheal disease history and associated
antimicrobial therapy.
Culture techniques. Of 77 patients whose speci-
mens were cultured for C. fetus, 54 had their stools
cultured on Skirrow medium (19). The plate medium
was incubated in a candle jar at 37°C and examined
daily for 3 days for colonies characteristic of C. fetus.
Specimens from the remaining 23 patients were cul-
tured on Campy-blood agar plates and in tubes of
thioglycolate broth containing the same antibiotics
found in Campy-BAP (4). The plate medium was
incubated in a large GasPak jar (BBL Microbiology
Systems, Cockeysville, Md.) by using two of the three
catalyst baskets and two carbon dioxide-hydrogen gas
generators. The plated medium was then processed, in
the same manner previously described, for specimens
obtained from the first 54 patients. The thioglycolate
broth was incubated for 18 to 24 h in a water bath at
42°C and then subcultured to Campy-BAP and incu-
bated as previously described. Colonies with morphol-
ogy similar to that observed with Campylobacter col-
onies were examined by wet mount and, when neces-
sary, further examined by Gram stain. Isolates which
showed darting motility and a Gram stain similar to
C. fetus were identified by using established tech-
niques for C. fetus (20).
Stool specimens were examined for C. difficile by
inoculating portions of each specimen onto a cycloser-
ine-cefoxitin-fructose agar plate (12) which was then
incubated in a GasPak jar for 48 h. Colonies ferment-
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ing fructose, not degrading lecithin, and exhibiting a
spreading margin were Gram stained and, when ap-
propriate, identified by the anaerobe identification
scheme of Holdeman et al. (14).
Stool examinations for ova and parasites were done
by direct mounts in saline and Lugol iodine and, on
occasion, by use of the trichrome stain (17). Stools
were also concentrated by using Formalin-ether con-
centration techniques (18) or a modified concentration
technique in which ethyl acetate was substituted for
ether (21). Stool concentrates were suspended in saline
and Lugol iodine and examined microscopically.
Salmonella and Shigella spp. were cultured by
inoculating 5% sheep blood, MacConkey, and Hektoen
agar plates (BBL) and a GN enrichment broth with
each specimen. The GN enrichment broth was sub-
cultured after 6 to 18 h incubation at 370C onto a
Hektoen and MacConkey agar plate. The blood agar
plate was used to detect overgrowth of the bowel flora
with gram-positive organisms or yeasts. The Mac-
Conkey and Hektoen plates were examined for non-
lactose-fermenting or hydrogen sulfide-producing or-
ganisms. Three colonies of each suspicious colony type
were screened by using a triple sugar iron agar, a lysine
iron agar, and a phenylalanine agar slant (8). Orga-
nisms with biochemical reactions consistent with those
of either Salmonella or Shigella species were identi-
fied to serogroup by using standard biochemical and
serological tests (8).
Yersinia enterocolitica was cultured by a cold en-
richment method. After primary culture onto the me-
dia described above for Salmonella and Shigella spp.,
a stool swab was placed in 1.0 ml of phosphate-
buffered saline and incubated for 3 weeks at 40C.
Subcultures were made weekly onto MacConkey and
salmonella-shigella agar, and these plates were incu-
bated at room temperature for 72 h. These culture
plates were examined daily for non-lactose-fermenting
colonies similar to Y. enterocolitica. These isolates
were characterized biochemically by using triple sugar
iron agar or phenylalanine agar and two tubes of
motility-indole-ornithine medium; one tube was incu-
bated at room temperature and the other was incu-
bated at 37°C. Organisms with biochemical reactions
consistent with those of Y. enterocolitica were iden-
tified by using appropriate biochemical tests (13). All
dehydrated media used during the course of this study
were supplied by either Difco Laboratories, Detroit,
Mich., or BBL, unless otherwise noted.
C. difficik toxin assay. Frozen stool specimens
were thawed in a water bath at 370C. A stool sample
(ca. 0.5 ml) was placed in a plastic snap-cap tube (12
by 75 mm) and diluted with an equal volume of phos-
phate-buffered saline containing 500 mg of cycloserine.
This mixture was mixed thoroughly and then centri-
fuged at 2,500 x g for 10 min. The stool supernatant
was removed and used for the toxin assay. Those
supernatants that either remained cloudy or contained
particulate matter after centrifugation were filtered
through a 0.45-,um membrane filter (Acrodisc; Gelman
Sciences, Inc., Ann Arbor, Mich.) before assay. Either
MRC-5 or WI-38 cells lines were grown in minimal
essential medium supplemented with 10% fetal calf
serum and 30 ,ug of gentamicin per ml. The cell mono-
layers were prepared by placement of 0.2 ml of cell
suspension (at ca. 105/ml) into each well of a 96-well
flat-bottomed microtiter tissue culture plate (Costar,
Cambridge, Mass.) and incubation at 37°C in 5% C02
until a monolayer formed. The assay for C. difficile
toxin was performed by placing 50 pl of 1:2 and 1:10
dilutions of each stool supernatant onto duplicate
monolayers of one of the two fibroblast cell mono-
layers.
The diluted stool supernatant fluids were incubated
with the cell monolayers at 370C in 5% C02 for 48 h.
The monolayers were examined at 12-h intervals dur-
ing the incubation period. Those monolayers showing
no morphological change after 48 h were considered
negative. Those monolayers showing actinomorphic
changes (2) in >50% of the cell monolayer treated with
the diluted stool supernatant were considered positive,
and a neutralization assay was performed on those
supernatants. Monolayers showing toxic changes such
as cell lysis or cell fusion were also tested in the
neutralization assay. Stool supernatants which caused
contamination of the monolayers by microorganisms
were filter sterilized as described above and again
assayed.
Culture supernatant from a known toxigenic strain
of C. difficile grown anaerobically in prereduced
chopped meat medium (Scott Laboratories, Fiske-
ville, R.I.) at 370C for 48 h was used as the positive
standard for this assay. This toxigenic strain was
kindly provided by V. R. Dowell of the Centers for
Disease Control. Atlanta, Ga.
Neutralization assay. Confirmation of the pres-
ence of C. difficile toxin in patient specimens required
the neutralization of cytotoxic activity with specific
antibody. Supernatants showing actinomorphic or
toxic changes at a 1:10 dilution were diluted in phos-
phate-buffered saline-cycloserine to give a final dilu-
tion of 1:10. The diluted supernatants were then mixed
with a 1:10 dilution of antiserum to C. difficile toxin
or a 1:10 dilution of fetal calf serum. The C. difficile
antitoxin (9) used in this study was kindly supplied by
Tracy Wilkins of the Virginia Polytechnic Institute
and State University. This mixture was incubated at
room temperature for 30 min, and 100 pl of the mixtur4
was assayed as described above. Specimens causing
cultured cells to demonstrate rounding in the presence
of fetal calf serum and no rounding in the presence of
C. difficile antitoxin were considered positive for the
toxin.
Determination of toxin titers. Toxin titers were
determined for each stool and culture supernatant
fluid which was proven to be positive by the neutrali-
zation assay. Serial 10-fold dilutions of the toxin sam-
ple from 10-1 to 10-6 were prepared in phosphate-
buffered saline-cycloserine, and 50,l of each dilution
was inoculated onto duplicate monolayers of either
MRC-5 or WI-38 fibroblasts. The cells were examined
for 48 h at 12-h intervals. The last dilution to give
greater than 50% rounding at 48 h was the toxin titer.
When the culture supernatant from the control organ-
ism was used, the two cell lines proved to be equally
susceptible to the toxin.
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RESULTS
Patient population. Of the 161 patients
studied, 91 (57%) developed diarrheal disease
outside the hospital. Eighty-six patients (54%)
were male, and 124 patients (76%) were over 25
years of age. A total of 129 patients (80%) had
diarrheal disease of less than 4 weeks in dura-
tion; 61 of these patients (47%) had diarrhea
associated with antimicrobial therapy, whereas
68 (53%) had diarrhea that was not associated
with antimicrobial therapy. There were 32 pa-
tients studied who had diarrheal disease of
greater than 4 weeks in duration; 16 of these
patients had chronic inflammatory bowel dis-
ease, and 16 had chronic diarrhea of unknown
etiology.
Culture results. Specimens from the 161 pa-
tients were examined for the presence of C.
difficile or its toxin. Specimens from 77, 113,
145, and 85 patients were examined for C. fetus,
intestinal parasites, Salmonella and Shigella
spp., and Yersinia sp., respectively. Specimens
from 139 patients were examined for three or
more of the five groups of organisms. As can be
seen in Table 1, C. difficile or its toxin was
encountered in 12% of the patients. Salmonella
sp. and Giardia lamblia were the only other
organisms which were observed to occur in more
than one patient. Y. enterocolitica and C. fetus
subsp. jejuni were isolated from one patient
each. Shigella sp. was not detected in any pa-
tient specimen. No patient studied had more
than one enteric pathogen detected in his or her
stools. Five additional patients who received
prior antibiotic therapy had stool cultures that
revealed an absence of Enterobacteriaceae and
a predominance of Pseudomonas aeruginosa or
yeasts.
Detection of C. difficile or its toxin. Of the
161 patients studied, specimens of 110 were ex-
amined for both C. difficile and its toxin; speci-
mens of 51 were tested for the presence of toxin
only. The results of culture and toxin assays
performed on the 19 patients whose specimens
TABLE 1. Recovery of enteric pathogens from
patients with diarrheal disease
No. of pa- No. (%) of pa-No.anioftip- tients with posi-Organism tients tv xma
studied tive examna-
C. fetus 77 1 (1.3)
C. difficile 161 19 (10.4)
Intestinal parasites' 113 4 (3.4)
Salmonella sp. 145 6 (4.1)
Shigella sp. 145 0 (0)
Yersinia sp. 82 1 (1.2)
a One Ascaris lumbricoides, three Giardia lamblia.
yielded C. difficile or its toxin were as follows.
In 13 patients, both the toxin and the organism
were present, in 4, only the toxin was detected,
and in 2, only the organism was detected. Of the
four patients in whom only C. difficile toxin was
detected, two were not cultured for the organism
and two were culture negative. One of the two
patients who was toxin positive and culture neg-
ative had been treated with oral vancomycin for
24 h before culture. C. difficile-associated diar-
rhea in these four patients was diagnosed by
detecting C. difficile toxin in their stool speci-
men(s). The relative concentration of C. difficile
toxin was determined for stool specimens ob-
tained from these 4 patients and for the 13
patients whose specimens were positive for both
toxin and culture. These 17 specimens were pos-
itive for toxin at dilutions ranging from 10' to
10-'. Specimens from 11 of 17 patients yielded
positive toxin assays with dilutions -2 x 102.
No difference was observed in the levels of toxin
present in stool specimens that were culture
positive when compared with those that were
culture negative.
Two patients had C. difficile detected in their
specimens by culture only. Assay for toxin on
these two stools was negative on three separate
occasions. Both strains were tested to determine
if they produced toxin in vitro. One of the two
strains produced a cytotoxin when it was grown
anaerobically in prereduced 1% glucose-chopped
meat broth. The toxin titer produced by this
organism in culture was 5 x 10-2. The patient
from whom this strain was recovered had mild
diarrheal disease which resolved without ther-
apy. The other strain that was recovered from a
specimen that did not contain free toxin failed
to produce the toxin when grown anaerobically.
This latter strain did not produce toxin when
grown in chopped meat-1% glucose, Schadler
broth, thioglycolate broth, and Trypticase soy
broth (BBL Microbiology Systems). The patient
suffered from several daily episodes of severe
diarrhea which resolved after empiric treatment
with oral vancomycin. C. difficile could not be
recovered from cultures of stool specimens ob-
tained after completion of 5 days of vancomycin
therapy.
Association of C. difficile with antibiotic
therapy. Of the 161 patients studied, 61 re-
ceived antimicrobial therapy before culture. Of
these patients, 17 (28%) had C. difficile or its
toxin present in their feces. No established en-
teric pathogen was found in specimens obtained
from these 61 patients.
Prior antibiotic therapy was not associated
with the remaining 100 patients studied, and C.
difficile was recovered from only two of these
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patients. One of these patients was a 2-year-old
female (positive C. difficile culture; stool toxin
concentration of 2 x 10-l) diagnosed as having
viral gastroenteritis and whose symptoms re-
solved without antimicrobial therapy. The other
patient was a 69-year-old male (stool toxin con-
centration of 1 x 10-2) who had diarrhea that
resolved with supportive therapy.
Antimicrobial agents most frequently admin-
istered to patients with diarrhea that was asso-
ciated with positive culture or toxin assays for
C. difficile were penicillins, cephalosporins, and
aminoglycosides. Penicillins were administered
in 12 of 17 patients who had toxin assays or
cultures positive for C. difficile. Cephalosporins
and aminoglycosides were each given to 11 pa-
tients. Prior therapy with clindamycin, chlor-
amphenicol, tetracycline, or trimethroprim-sul-
famethoxazole was also associated with two or
more patients that developed diarrhea and
whose specimens were toxin- or culture-positive
for C. difficile. Of these 17 patients, 11 received
simultaneous therapy with two or more antimi-
crobial agents, one always being an aminogly-
coside. Six additional patients were treated with
only one antibiotic which was either a penicillin
or cephalosporin. The time of onset of disease
after initiation of antimicrobial therapy ranged
from 2 to 23 days with an average of 13 days.
The patients who had antimicrobial agent-as-
sociated diarrhea with a positive C. difficile cul-
ture or toxin assay were older than 25 years.
Only 5 of 12 patients who had disease caused by
other enteric pathogens were older than 25.
Three of these latter five patients had G. lam-
blia infections. Neither C. difficile nor any other
enteric pathogen was found to be associated with
diarrheal disease of greater than four weeks du-
ration. All cases of diarrhea caused by estab-
lished enteric pathogens were outpatients. The
two patients who had C. difficile-associated dis-
ease but did not have a history of prior antimi-
crobial therapy also developed disease outside
the hospital. Of the 17 patients with antimicro-
bial associated diarrhea with evidence of C. dif-
ficile, 12 developed symptoms during hospitali-
zation, and five developed symptoms as outpa-
tients. Three of the latter five developed symp-
toms before hospitalization, whereas the other
two developed symptoms less than a month after
release from the hospital.
Sigmoidoscopic examinations were per-
formed on 70 of 161 patients studied (Table 2).
The examination results were reported as either
normal, nonspecific colitis (including inflamma-
tory bowel disease), or pseudomembranous col-
itis. If the patients with inflammatory bowel
disease were eliminated from the C. difficile-
TABLE 2. Sigmoidoscopic examination ofpatients
with diarrheal disease






Antibiotic treatment 3 7 2
No antibiotic treat- 0 1 0
ment
C. difficile negative
Antibiotic treatment 10 8 0
No antibiotic treat- 13 11 0
ment
Inflammatory bowel 2 13 0
disease
a Individuals had toxin or organism or both present in their
stool specimens.
negative patients, C. difficile-positive patients
had a higher percentage of abnormal sigmoidos-
copies (77%) as compared with the C. difficile-
negative patients (48%). In addition, pseudo-
membranes were seen on sigmoidoscopy in two
of the C. difficile-positive patients, but in none
of the C. difficile-negative patients.
Since the disease of most patients who were
C. difficile culture- or toxin-positive or both was
resolved by using either supportive therapy (dis-
continuing antibiotics, using fluid therapy, and
administration of Lomotil) or vancomycin ther-
apy, few follow-up data on this group of patients
were available. Almost all of the patients in-
cluded in this study who had multiple specimnens
tested had neither C. difficile nor an established
pathogen recovered. One patient who was posi-
tive at admission, by both culture and toxin
assay for C. difficile, was closely studied for a
period of 2 months. She was treated for 2 weeks
with oral tetracycline, 3 weeks before admission.
At admission, she had severe diarrheal disease.
A sigmoidoscopic examination at that time re-
vealed diffuse edema and local inflammation,
but no pseudomembranes were seen. She was
also culture- and toxin-positive for C. difficile.
Oral vancomycin (500 mg twice a day) was ad-
ministered for 5 days, and her diarrhea quickly
resolved. Toxin and culture studies 2 weeks after
cessation of therapy were both negative. She
was readmitted 10 days later with severe diar-
rhea and, again, was culture- and toxin-positive
with a 10-fold increase in her stool toxin titer.
She was again treated with the same course of
vancomycin previously given and her disease
once again resolved. A week after the cessation
of therapy she was again culture and toxin neg-
ative and did not return with any symptoms for
the next 6 months.
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DISCUSSION
C. difficile has been implicated as an impor-
tant etiological agent ofantimicrobial-associated
diarrhea and pseudomembranous colitis (1-3,
11). However, the relative frequency of this or-
ganism in patients with diarrheal disease in com-
parison to that of other enteric pathogens is not
known. Our results indicate that C. difficile is
an organism that may be commonly recovered
from patients with diarrheal disease in our insti-
tution. A total of 90% of the C. difficile-positive
patients were receiving or recently received an-
tibiotic therapy; this supports the view that an-
tibiotic therapy was an important predisposing
factor for the establishment of C. difficile in the
intestine (1-3, 11). Our finding that 100% of
patients with pseudomembranous colitis and
27% of patients with antibiotic-associated diar-
rheal disease harbored C. difficile agreed with
the finding of Bartlett et al. (3). In addition, we
found that the concentrations of C. difficile toxin
in the stools we examined were similar to those
reported by Bartlett et al. (2). These investiga-
tors observed that the concentration of toxin
varied widely in patients with C. difficile-asso-
ciated pseudomembranous colitis, and they as-
cribed this fmding to the differing number of
organisms present in the stool specimens they
tested. In our patient population, there appeared
to be no correlation between toxin titer and
severity of disease. However, patients whose
specimens were positive for C. difficile had a
higher percentage of abnormal sigmoidoscopic
examinations when compared with patients
whose stools were negative for C. difficile, sug-
gesting a role for C. difficile in the pathogenesis
of disease in our patient population. Further
support for such a role in antibiotic-associated
diarrheal disease was that therapy effective in
pseudomembranous colitis caused by C. difficile
was also effective in at least one patient with
antibiotic-associated diarrhea with positive cul-
tures and toxin assays. Many questions concern-
ing the pathogenesis of antibiotic-associated
diarrhea and the possible role of C. difficile in
this disease remain unanswered.
Two or our patients had stool specimens
which did not contain toxin but had cultures
that yielded C. difficile. One of the patients had
a toxigenic organism and mild diarrheal disease
which resolved without treatment. The role that
C. difficile may have played in this patient's
diarrhea is difficult to assess. The other patient
had severe diarrhea that resolved with oral van-
comycin therapy and elimination of a nontoxi-
genic strain of C. difficile from stool specimens.
The observation of disease associated with the
presence of a nontoxigenic strain of C. difficile
may be coincidental or may suggest that the C.
difficile produces another toxin(s) which may
play a role in diarrheal disease. Clostridia, such
as C. perfringens, produce multiple toxins (16).
Therefore, the production of multiple toxins by
C. difficile would not be unusual.
It has recently been reported that C. difficile
may play a role in relapse in chronic inflamma-
tory bowel disease (5, 15). None of the 16 pa-
tients included in our study who had inflamma-
tory bowel disease and were suffering relapse
had stool specimens positive for C. difficile or
its toxin.
The role for C. difficile as a cause of pseudo-
membranous colitis is well established (1-3, 11).
Data presented here and by Bartlett et al. (3)
suggest that C. difficile may play an important
role in the pathogenesis of antibiotic-associated
diarrhea. Because of the proven and possible
importance of this organism in severe diarrheal
disease, clinical laboratories in tertiary care fa-
cilities should consider establishing techniques
for the detection of C. difficile and its toxin.
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